Search Result

Isoforms Recommended:	HIF

Results for "

HIF2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (4) HIF/HIF Prolyl-Hydroxylase (37) Isotope-Labeled Compounds (1) JNK (2) MMP (1) Natriuretic Peptide Receptor (NPR) (1) p38 MAPK (2) Ras (1) Reactive Oxygen Species (ROS) (2) Reference Standards (2) Xanthine Oxidase (4)
By Research Areas:	Cancer (39) Cardiovascular Disease (1) Infection (8) Inflammation/Immunology (11) Metabolic Disease (6) Neurological Disease (4)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-136748

HIF-2α-IN-4 1 Publications Verification	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-2α-IN-4 is a potent inhibitor of hypoxia inducible factor-2α (HIF-2α) translation, with an IC₅₀ of 5 μM. HIF-2α-IN-4 decreases both constitutive and hypoxia-induced HIF-2α protein expression. HIF-2α-IN-4 links its 5'UTR iron-responsive element to oxygen sensing .

HY-144178

HIF-2α-IN-6	HIF/HIF Prolyl-Hydroxylase	Others
HIF-2α-IN-6 (117) is a *HIF-2α* inhibitor .

HY-144176

HIF-2α-IN-5	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-2α-IN-5 is a potent *HIF-2α* inhibitor with an IC₅₀ of < 50 nM .

HY-163598

HIF-2α-IN-11	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-2α-IN-11 (1) is a *HIF-2α* inhibitor, with an IC₅₀ of 59.2 nM .

HY-163601

HIF-2α-IN-14	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-2α-IN-14 (18) is a *HIF-2α* inhibitor, with an IC₅₀ of 0.27 μM .

HY-163602

HIF-2α-IN-15	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-2α-IN-15 (35) is a *HIF-2α* inhibitor, with an IC₅₀ of 0.41 μM .

HY-163600

HIF-2α-IN-13	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-2α-IN-13 (18) is a *HIF-2α* inhibitor, with an IC₅₀ of 2.7 μM .

HY-163599

HIF-2α-IN-12	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-2α-IN-12 (9) is a *HIF-2α* inhibitor, with an IC₅₀ of 0.9 μM .

HY-163597

HIF-2α-IN-10	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-2α-IN-10 (17) is a *HIF-2α* inhibitor, with an IC₅₀ of 0.05 μM .

HY-163603

HIF-2α-IN-16	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-2α-IN-16 (48) is a *HIF-2α* inhibitor, with an IC₅₀ of 0.091 μM .

HY-19949

HIF-2α-IN-1 1 Publications Verification	HIF/HIF Prolyl-Hydroxylase	Metabolic Disease
HIF-2α-IN-1 (compound 9b) is a *HIF-2α* inhibitor (IC₅₀=1.7 μM, SPA/scintillation proximity assay) .

HY-130264

HIF-2α-IN-2	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-2α-IN-2 is a hypoxia-inducible factors (HIF-2α) inhibitor extracted from patent WO2015035223A1, Compound 232, has an IC₅₀ of 16 nM in scintillation proximity assay (SPA) .

HY-18370

HIF-2α-IN-3	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-2α-IN-3, an allosteric inhibitor of hypoxia inducible factor-2α (HIF-2α), exhibits an IC₅₀ of 0.4 µM and a K_D of 1.1 µM. Anticancer agent .

HY-148264

Imdatifan HIF-2α-IN-7	HIF/HIF Prolyl-Hydroxylase	Infection Metabolic Disease Inflammation/Immunology Cancer
Imdatifan (HIF-2α-IN-7) is a hypoxia inducible factor 2α (HIF-2α) inhibitor. Imdatifan can inhibit HIF-2α with an EC₅₀ value of 6 nM. Imdatifan can be used for the research of various types of diseases including cancer, liver disease, inflammatory disease, pulmonary diseases and iron load disorders .

HY-153016

HIF-2α agonist 2	HIF/HIF Prolyl-Hydroxylase	Inflammation/Immunology
HIF-2α agonist 2 (compound 10) is a *HIF-2α* agonist with an EC₅₀ value of 1.68 μM at the dose of 20 μM. HIF-2α agonist 2 is non-cytotoxic against 786-O-HRE-Luc cells. HIF-2α agonist 2 can be used for oxygen metabolism research .

HY-161265

HIF-2α agonist 3	HIF/HIF Prolyl-Hydroxylase	Metabolic Disease
HIF-2α agonist 3 (Compound 14d) is an orally active *HIF-2α* agonist with a EC₅₀ value of 1.78 μM. HIF-2α agonist 3 can be used in the study of renal anemia .

HY-149886

HIF-2α-IN-9	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-2α-IN-9 (compound 35r) is an inhibitor ofHIF-2α. HIF-2α-IN-9 inhibits VEGF-A (IC₅₀=305 nM), and regulates growth-promoting genes in tumor cells, reactivates macrophage-mediated tumor immunity .

HY-148860

NVP-DFF332 HIF-2α-IN-8	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-2α-IN-8 is a potent and orally active *HIF2α* inhibitor with IC₅₀ values of 9, 37, 246 nM for HIF2α SPA, HIF2α iScript, HIF2α HRE RGA, respectively. HIF-2α-IN-8 shows antitumor activity .

HY-139287

M1002 1 Publications Verification	HIF/HIF Prolyl-Hydroxylase	Cancer
M1002 is a hypoxia-inducible factor-2 (HIF-2) agonist, and can enhance the expression of HIF-2 target genes. M1002 shows synergy with prolyl-hydroxylase domain (PHD) inhibitors .

HY-121728

Langkamide	Others	Others
Langkamide is a novel hypoxia-inducible factor-2 (HIF-2) inhibitory pyrrolidone alkaloid isolated from the roots and stems of Piper sarmentosum, which inhibits HIF-2 transcriptional activity with an EC value of 14.0μM.

HY-B2171A

Carubicin hydrochloride Carminomycin hydrochloride; Carminomicin I hydrochloride	Apoptosis	Infection Cancer
Carubicin hydrochloride is a microbially-derived compound. Carubicin hydrochloride is an effective inhibitor of VHL-defective (VHL−/−) CCRCC cell proliferation. Carubicin hydrochloride also induces apoptosis by a mechanism independent of p53 or hypoxia-inducible factor HIF2. Carubicin hydrochloride has the potential for the research of cancer diseases ^[2].

HY-B2171

Carubicin Carminomycin; Carminomicin I	Apoptosis	Infection Cancer
Carubicin (Carminomycin) is a microbially-derived compound. Carubicin is an effective inhibitor of VHL-defective (VHL−/−) CCRCC cell proliferation. Carubicin also induces apoptosis by a mechanism independent of p53 or hypoxia-inducible factor HIF2. Carubicin has the potential for the research of cancer diseases ^[2].

HY-P10223

Cyclo(CRVIIF)	HIF/HIF Prolyl-Hydroxylase	Cancer
Cyclo CRVIIF is a dual inhibitor for hypoxia inducible factor (HIF) 1 and 2, which disrupts the interaction of both HIF1-α and HIF2-α with HIF1-β, with affinity for HIF1-α and HIF2-α PAS-B domains K_D of 65 and 123 μM, respectively .

HY-P10222

Cyclo(CRLLIF)	HIF/HIF Prolyl-Hydroxylase	Cancer
Cyclo CRLLIF is a dual inhibitor for hypoxia inducible factor (HIF) 1 and 2, which disrupts the interaction of both HIF1-α and HIF2-α with HIF1-β, with affinity for HIF1-α and HIF2-α PAS-B domains K_D of 14.5 and 10.2 μM, respectively .

HY-P10221A

Cyclo(CKLIIF) TFA	HIF/HIF Prolyl-Hydroxylase	Cancer
Cyclo CKLIIF is a dual inhibitor for hypoxia inducible factor (HIF) 1 and 2, which disrupts the interaction of both HIF1-α and HIF2-α with HIF1-β, with affinity for HIF1-α and HIF2-α PAS-B domains K_D of 2.6 and 2.2 μM, respectively .

HY-19621

THS-044	HIF/HIF Prolyl-Hydroxylase	Cancer
THS-044 binding stabilizes the HIF2α PAS-B folded state, for regulating HIF2 activity in endogenous and clinical settings.

HY-44809

Izilendustat	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease Inflammation/Immunology
Izilendustat is a potent inhibitor of prolyl hydroxylase which can stabilize hypoxia inducible factor- 1 alpha (HIF- lα) and hypoxia inducible factor-2 (HIF-2). Izilendustat has the potential for researching diseases that relate to the body’s inmmune response like colitis and other inflammatory bowel diseases (extracted from patent WO2011057115A1 and WO2011057121A1) .

HY-44809A

Izilendustat hydrochloride	HIF/HIF Prolyl-Hydroxylase	Inflammation/Immunology Cancer
Izilendustat (hydrochloride) is a potent inhibitor of prolyl hydroxylase which stabilizes hypoxia inducible factor- 1 alpha (HIF- lα), as well as hypoxia inducible factor-2 (HIF-2). Izilendustat (hydrochloride) has the potential for the research of HIF- lα related diseases including Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, anemia, colitis, and other inflammatory bowel diseases (extracted from patent WO2011057115A1/WO2011057112A1/WO2011057121A1) ^[2] .

HY-18371

TC-S 7009 1 Publications Verification	HIF/HIF Prolyl-Hydroxylase	Inflammation/Immunology
TC-S 7009 is a potent and selective *HIF-2α* inhibitor with a K_d of 81 nM. TC-S 7009 is more selective for *HIF-2α* than HIF-1α (K_d ? 5 μM). TC-S 7009 disrupts *HIF-2α* heterodimerization, decreases DNA-binding activity, and reduces *HIF-2α* target gene expression ^[2].

HY-177078

Davotifan	HIF/HIF Prolyl-Hydroxylase	Cancer
Davotifan (Compound A17) is a bicyclic compound. Davotifan is an inhibitor of *HIF-2α. Davotifan can be studied in research for HIF-2*α-related cancer .

HY-108697

PT2399 5+ Cited Publications	HIF/HIF Prolyl-Hydroxylase	Cancer
PT2399 is a potent and selective *HIF-2α* antagonist, which directly binds to HIF-2α PAS B domain with an IC₅₀ of 6 nM. PT2399 displays potent antitumor activity in vivo ^[2] .

HY-111547

M1001	HIF/HIF Prolyl-Hydroxylase	Cancer
M1001 is a weak hypoxia-inducible factor-2α (HIF-2α) agonist. M1001 can bind to the HIF-2α PAS-B domain, with a K_d of 667 nM. M1001 can be used in chronic kidney disease research .

HY-125840

Belzutifan 5+ Cited Publications PT2977; MK-6482	HIF/HIF Prolyl-Hydroxylase	Cancer
Belzutifan (PT2977) is an orally active and selective *HIF-2α* inhibitor with an IC₅₀ of 9 nM. Belzutifan, as a second-generation HIF-2α inhibitor, increases potency and improves pharmacokinetic profile. Belzutifan is a potential treatment for clear cell renal cell carcinoma (ccRCC) .

HY-12867

PT-2385 Maximum Cited Publications 49 Publications Verification	HIF/HIF Prolyl-Hydroxylase	Cancer
PT-2385 is a selective *HIF-2α* inhibitor with a K_i of less than 50 nM ^[2].

HY-125840R

Belzutifan (Standard)	HIF/HIF Prolyl-Hydroxylase	Cancer
Belzutifan (Standard) is the analytical standard of Belzutifan. This product is intended for research and analytical applications. Belzutifan (PT2977) is an orally active and selective HIF-2α inhibitor with an IC50 of 9 nM. Belzutifan, as a second-generation HIF-2α inhibitor, increases potency and improves pharmacokinetic profile. Belzutifan is a potential treatment for clear cell renal cell carcinoma (ccRCC) .

HY-108697A

(Rac)-PT2399	HIF/HIF Prolyl-Hydroxylase	Cancer
(Rac)-PT2399 (Compound 10e), the racemate of PT2399, acts as a potent and specific hypoxia-inducible factor 2a *(HIF-2α)* inhibitor with an IC₅₀ of 0.01 μM .

HY-151341

HIF-1/2α-IN-1	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-1/2α-IN-1 is an orally active *HIF-2α* inhibitor. HIF-1/2α-IN-1 inhibits HIF-2α activity with an IC₅₀ value of 0.92 μM. HIF-1/2α-IN-1 also can decrease HIF-1α levels. HIF-1/2α-IN-1 can be used for the research of clear cell renal cell carcinoma (ccRCC) .

HY-159644

Casdatifan AB521	HIF/HIF Prolyl-Hydroxylase	Cancer
Casdatifan (AB521) is an orally active HIF-2α (hypoxia-inducible factor 2α) inhibitor. Casdatifan exhibited significant antitumor activity and favorable pharmacokinetics in ccRCC (clear cell renal cell carcinoma) models .

HY-113649

AKB-6899	HIF/HIF Prolyl-Hydroxylase	Cancer
AKB-6899, a prolyl hydroxylase domain 3 (PHD3) inhibitor, is a selective *HIF-2α* stabilizer. AKB-6899 also increases soluble form of the VEGF receptor (sVEGFR-1) production from GM-CSF-treated macrophages, and has antitumor and antiangiogenic effects .

HY-139855

ZG-2033	HIF/HIF Prolyl-Hydroxylase	Metabolic Disease
ZG-2033 (Compound 26) is an orally active *HIF-2α* agonist that demonstrates nanomolar activity in luciferase reporter gene assays (EC₅₀ = 490 nM). ZG-2033 has the effect of alleviating anemia and exhibits synergistic action with AKB-6548 (HY-101277) in anemia, and can be used in the study of renal anemia .

HY-B0219A

Allopurinol sodium 5+ Cited Publications	Xanthine Oxidase	Infection Neurological Disease Inflammation/Immunology Cancer
Allopurinol sodium is a potent and orally active xanthine oxidase inhibitor with an IC₅₀ value of 0.2-50 μM. Allopurinol sodium can be used in the research of hyperuricemia and gout. Allopurinol sodium decreases the expression of HIF-1α and HIF-2α protein. Allopurinol sodium shows anti-depressant and anti-nociception activity. Anti-leishmanial effect ^[2] .

HY-B0219

Allopurinol 5+ Cited Publications	Xanthine Oxidase	Infection Neurological Disease Inflammation/Immunology Cancer
Allopurinol is a potent and orally active xanthine oxidase inhibitor with an IC₅₀ value of 0.2-50 μM. Allopurinol can be used in the research of hyperuricemia and gout. Allopurinol decreases the expression of HIF-1α and HIF-2α protein. Allopurinol shows anti-depressant and anti-nociception activity. Anti-leishmanial effect ^[2] .

HY-B2171AR

Carubicin hydrochloride (Standard) Carminomycin hydrochloride (Standard); Carminomicin I hydrochloride (Standard)	Reference Standards Apoptosis	Infection Cancer
Isoflavone (Standard) is the analytical standard of Isoflavone. This product is intended for research and analytical applications. Isoflavone is an orally available bioactive component of soy phytoestrogen with lipid-lowering and antioxidant activities. Isoflavone prevents a variety of chronic diseases by regulating fatty acid oxidation in the liver and gene expression in adipose tissue. In addition, isoflavone has important value in the research of cancer and cardiovascular diseases ^[2] .

HY-B0219R

Allopurinol (Standard)	Reference Standards Xanthine Oxidase	Infection Neurological Disease Inflammation/Immunology Cancer
Allopurinol (Standard) is the analytical standard of Allopurinol. This product is intended for research and analytical applications. Allopurinol is a potent and orally active xanthine oxidase inhibitor with an IC50 value of 0.2-50 μM. Allopurinol can be used in the research of hyperuricemia and gout. Allopurinol decreases the expression of HIF-1α and HIF-2α protein. Allopurinol shows anti-depressant and anti-nociception activity. Anti-leishmanial effect ^[2] .

HY-111431

p-Cresyl sulfate 5 Publications Verification p-Tolyl sulfate	JNK p38 MAPK Reactive Oxygen Species (ROS)	Metabolic Disease
p-Cresyl sulfate (p-Tolyl sulfate) is a uremic toxin, that can cause renal damage and dysfunction. p-Cresyl sulfate shows antiproliferation activity. p-Cresyl sulfate increases the protein expression of HIF-1α and VHL, decreases the protein expression of HIF-2α. p-Cresyl sulfate induces epithelial-mesenchymal transition (EMT). p-Cresyl sulfate activates the JNK and p38 MAPK signaling pathways ^[2] .

HY-B0219S1

Allopurinol-13C,15N2	Isotope-Labeled Compounds Xanthine Oxidase	Infection Neurological Disease Inflammation/Immunology Cancer
Allopurinol- ¹³C, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled labeled Allopurinol (HY-B0219). Allopurinol is a potent and orally active xanthine oxidase inhibitor with an IC₅₀ value of 0.2-50 μM. Allopurinol can be used in the research of hyperuricemia and gout. Allopurinol decreases the expression of HIF-1α and HIF-2α protein. Allopurinol shows anti-depressant and anti-nociception activity. Anti-leishmanial effect ^[2] .

HY-111431AR

p-Cresyl sulfate potassium (Standard)	JNK p38 MAPK Reactive Oxygen Species (ROS)	Metabolic Disease
p-Cresyl sulfate (potassium) (Standard) is the analytical standard of p-Cresyl sulfate (potassium). This product is intended for research and analytical applications. p-Cresyl sulfate (p-Tolyl sulfate) potassium is a uremic toxin, that can cause renal damage and dysfunction. p-Cresyl sulfate potassium shows antiproliferation activity. p-Cresyl sulfate potassium increases the protein expression of HIF-1α and VHL, decreases the protein expression of HIF-2α. p-Cresyl sulfate potassium induces epithelial-mesenchymal transition (EMT). p-Cresyl sulfate potassium activates the JNK and p38 MAPK signaling pathways ^[2] .

HY-P10869

dCNP 1 Publications Verification	Natriuretic Peptide Receptor (NPR)	Inflammation/Immunology Cancer
dCNP binds to NPR-B/C receptor, activates cGMP signaling pathway, and regulates vascular function. dCNP exhibits anti-hypoxia property through downregulation of hypoxia-related genes expressions like HIF1α and HIF2α. dCNP inhibits the induction of tumor stroma and exhibits anti-fibrosis activity. dCNP upregulates CTLs, NK cells, and conventional type 1 dendritic cells in tumors, and activates immune responses .

HY-120793

CMC2.24 TRB-N0224	Ras Apoptosis MMP	Inflammation/Immunology Cancer
CMC2.24 (TRB-N0224), an orally active tricarbonylmethane agent, is effective against pancreatic tumor in mice by inhibiting Ras activation and its downstream effector ERK1/2 pathway. CMC2.24 is also a potent inhibitor of zinc-dependent MMPs with IC₅₀s ranging from 2.0-69 μM. CMC2.24 alleviates osteoarthritis progression by restoring cartilage homeostasis and inhibiting chondrocyte apoptosis via the NF-κB/HIF-2α axis ^[2] .

Cat. No.	Product Name	Target	Research Area

HY-P10221A

Cyclo(CKLIIF) TFA	HIF/HIF Prolyl-Hydroxylase	Cancer
Cyclo CKLIIF is a dual inhibitor for hypoxia inducible factor (HIF) 1 and 2, which disrupts the interaction of both HIF1-α and HIF2-α with HIF1-β, with affinity for HIF1-α and HIF2-α PAS-B domains K_D of 2.6 and 2.2 μM, respectively .

HY-P10869

dCNP 1 Publications Verification	Natriuretic Peptide Receptor (NPR)	Inflammation/Immunology Cancer
dCNP binds to NPR-B/C receptor, activates cGMP signaling pathway, and regulates vascular function. dCNP exhibits anti-hypoxia property through downregulation of hypoxia-related genes expressions like HIF1α and HIF2α. dCNP inhibits the induction of tumor stroma and exhibits anti-fibrosis activity. dCNP upregulates CTLs, NK cells, and conventional type 1 dendritic cells in tumors, and activates immune responses .

HY-P10223

Cyclo(CRVIIF)	HIF/HIF Prolyl-Hydroxylase	Cancer
Cyclo CRVIIF is a dual inhibitor for hypoxia inducible factor (HIF) 1 and 2, which disrupts the interaction of both HIF1-α and HIF2-α with HIF1-β, with affinity for HIF1-α and HIF2-α PAS-B domains K_D of 65 and 123 μM, respectively .

HY-P10222

Cyclo(CRLLIF)	HIF/HIF Prolyl-Hydroxylase	Cancer
Cyclo CRLLIF is a dual inhibitor for hypoxia inducible factor (HIF) 1 and 2, which disrupts the interaction of both HIF1-α and HIF2-α with HIF1-β, with affinity for HIF1-α and HIF2-α PAS-B domains K_D of 14.5 and 10.2 μM, respectively .

Cat. No.	Product Name	Chemical Structure

HY-B0219S1

Allopurinol-13C,15N2

Allopurinol- ¹³C, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled labeled Allopurinol (HY-B0219). Allopurinol is a potent and orally active xanthine oxidase inhibitor with an IC₅₀ value of 0.2-50 μM. Allopurinol can be used in the research of hyperuricemia and gout. Allopurinol decreases the expression of HIF-1α and HIF-2α protein. Allopurinol shows anti-depressant and anti-nociception activity. Anti-leishmanial effect ^[2] .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P84756

	HIF-2 alpha Antibody (YA4453) HLF; MOP2; ECYT4; HIF2A; PASD2; bHLHe73	IHC-P, ICC/IF, FC, ELISA	Human
	HIF-2 alpha Antibody (YA4453) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to HIF-2 alpha.

HY-P81700

	HIF-2 alpha Antibody (YA1445) bHLHe73; ECYT4; EPAS 1; EPAS1; HIF2A; HLF; MOP 2; PASD2	WB, ICC/IF, FC	Human, Mouse, Rat
	HIF-2 alpha Antibody (YA1445) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HIF-2 alpha.

HY-P81153

	HIF-2 alpha Antibody (YA3517) Basic helix loop helix PAS protein MOP2; Basic-helix-loop-helix-PAS protein MOP2; bHLHe73; Class E basic helix-loop-helix protein 73; ECYT4; Endothelial PAS domain containing protein 1; Endothelial pas domain protein 1; Endothelial PAS domain-containing protein 1; EPAS 1; EPAS-1; EPAS1; EPAS1_HUMAN; HIF 1 alpha like factor; HIF-1-alpha-like factor; HIF-2-alpha; HIF2-alpha; HIF2A; HLF; Hypoxia inducible factor 2 alpha; Hypoxia inducible factor 2 alpha subunit; Hypoxia-inducible factor 2-alpha; Member of PAS protein 2; Member of pas superfamily 2; MOP 2; MOP2; PAS domain-containing protein 2; PASD2.	WB, IHC-P, FC	Human, Mouse, Rat
	HIF-2 alpha Antibody (YA3517) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HIF-2 alpha.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks